IKT News and Press, Inhibikase Therapeutics Inc. From 08/11/22

Major earnings expected after the bell on Friday include: Sundial Growers   ( SNDL ) Beam Global   ( BEEM ) Virgin Orbit Holdings  ( VORB ) American Shared Hospital Services  ( AMS ) Inhibikase Therapeutics  ( IKT ...

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022 PR Newswire BOSTON and ATLANTA , Aug. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...

Inhibikase (NASDAQ:IKT) said on Monday it was starting its Phase 2a study testing IkT-148009 to treat Parkinson's disease, following review of the study protocol and Phase 1/1b data by the U.S. Food and Drug Administration. The company said the Phase 2a trial, dubbed 201, was open f...

Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review PR Newswire Phase 1/ 1b '101' study terminated early; demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and mu...

Inhibikase Therapeutics, Inc. (IKT) Q1 2022 Earnings Conference Call May 17, 2022 08:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Conference Call Participants Presentation Operator Greeti...

Inhibikase Therapeutics press release (NASDAQ:IKT): Q1 GAAP EPS of -$0.18. Revenue of $0.05M (-96.5% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.05M

Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call and webcast on Tuesday, May 17, 2022 , at 8:00am ET BOSTON and ATLANTA , May 16, 2022 ...

Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference PR Newswire BOSTON and ATLANTA , May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical comp...

Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 PR Newswire BOSTON and ATLANTA , May 9, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference PR Newswire BOSTON and AT...